TY  - JOUR
AU  - Leichsenring, Jonas
AU  - Volckmar, Anna-Lena
AU  - Magios, Nikolaus
AU  - Morais de Oliveira, Cristiano Manuel
AU  - Penzel, Roland
AU  - Brandt, Regine
AU  - Kirchner, Martina
AU  - Bozorgmehr, Farastuk
AU  - Thomas, Michael
AU  - Schirmacher, Peter
AU  - Warth, Arne
AU  - Endris, Volker
AU  - Stenzinger, Albrecht
TI  - Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
JO  - Genes, chromosomes & cancer
VL  - 56
IS  - 3
SN  - 1045-2257
CY  - New York, NY
PB  - Wiley-Liss
M1  - DKFZ-2017-00900
SP  - 214 - 220
PY  - 2017
AB  - Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9
LB  - PUB:(DE-HGF)16
C6  - pmid:27750395
DO  - DOI:10.1002/gcc.22427
UR  - https://inrepo02.dkfz.de/record/120471
ER  -